Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease.
about
Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Co-targeting the HER and IGF/i ...... for hormone-sensitive disease.
@en
Co-targeting the HER and IGF/i ...... for hormone-sensitive disease.
@nl
type
label
Co-targeting the HER and IGF/i ...... for hormone-sensitive disease.
@en
Co-targeting the HER and IGF/i ...... for hormone-sensitive disease.
@nl
prefLabel
Co-targeting the HER and IGF/i ...... for hormone-sensitive disease.
@en
Co-targeting the HER and IGF/i ...... for hormone-sensitive disease.
@nl
P2860
P1476
Co-targeting the HER and IGF/i ...... for hormone-sensitive disease.
@en
P2093
Ashok Chakraborty
P2860
P2888
P356
10.1007/S10549-017-4169-9
P407
P577
2017-02-24T00:00:00Z